



ABN 58 008 130 336  
Suite 6, Level 3  
320 Adelaide Street  
Brisbane QLD 4000  
Ph 07 3229 5755  
Fax 07 3229 4655

11 June 2010

**The Manager**  
**Company Announcements**  
**Australian Stock Exchange**  
**Level 4, 20 Bridge Street**  
**Sydney, NSW 2000**

## **BioProspect's new *GI-Guard*<sup>™</sup> horse treatment submitted for regulatory approval**

### **Highlights**

- BioProspect submits registration application for *GI-Guard*<sup>™</sup> Oral Paste for Horses to the Australian Pesticides & Veterinary Medicines Authority (APVMA)
- New natural low toxicity product aimed at improving the health and well-being of horses, including conditions such as equine gastric ulcer syndrome (EGUS) which affects more than 50% of performance horses
- Anticipated 12 month timeframe for regulatory approval, with phased submission of product chemistry and efficacy/safety data to enable parallel review
- Australian registration to assist registration in other key regional markets, with product range including *AGRIPRO*<sup>™</sup> Topical Gel targeting A\$15bn a year global animal health products market
- Positive investor response to Share Purchase Plan, boosting commercialisation funds

Australian natural products provider BioProspect Limited (ASX:BPO) today announced the submission of a registration application with the APVMA for the Company's new *GI-Guard*<sup>™</sup> Oral Paste for Horses, targeting product approval within 12 months.

Comprised of 90 per cent Conifer Green Needle Complex (CGNC) - a natural substance with low toxicity extracted from the green needles of Scots Pine and Norway Spruce trees – the new product can be administered for general health and well-being of the gastro-intestinal tract, and for alleviating symptoms associated with EGUS.

BioProspect's Chief Operating Officer, Peter May, said the registration application was an important step towards the commercialisation of a range of natural *AGRIPRO*<sup>™</sup> products for the global \$15 billion animal health products market.

“BioProspect is moving quickly to commercialise its new *AGRIPRO*<sup>™</sup> brand products, aided by new APVMA guidelines which have cut the registration timeframe to within 12 months,” Mr May said.

“Safety studies have already successfully been completed on both the *GI-Guard*<sup>™</sup> Oral Paste and the *AGRIPRO*<sup>™</sup> Topical Gel (containing 7.5 per cent CGNC), and we will be launching additional efficacy studies to complete the data package for these products’ registration.”

He said the Company’s phased application for *GI-Guard*<sup>™</sup> Oral Paste involved the initial submission of product chemistry data under the Part 2 category, with an eight-month review period. This would be followed by the parallel submission of additional efficacy and safety data under the Part 8 category, with a four-month review period. Including additional time for the application’s screening and approval finalisation, the registration process should be completed within 12 months.

CGNC is already listed with the Australian Therapeutics Goods Administration for use in complementary human medicine, thereby minimising toxicological review by the APVMA under the Part 3 category.

“BioProspect envisages the registration process for *GI-Guard*<sup>™</sup> Oral Paste being completed within a year, which would then allow for registration in key regional markets for companion animals,” he said.

“Demand for natural, environmentally friendly alternatives continues to grow, and based on the interest following our previous trials conducted in the United Arab Emirates and locally, we anticipate rapid market development of *AGRIPRO*<sup>™</sup> products.”

Naturally derived *GI-Guard*<sup>™</sup> Oral Paste is seen as having potential for its affect not only on ulcers, but also for its long-term impact on metabolism in aiding infection control and recovery. *AGRIPRO*<sup>™</sup> Topical Gel has been developed for the treatment of surface wounds and abrasions, which represents a significant component of the equine healthcare market.

Mr May said that preparations were underway to test *GI-Guard*<sup>™</sup> Oral Paste on thoroughbred horses in training, with another study on *AGRIPRO*<sup>™</sup> Topical Gel planned to confirm efficacy and enable a comprehensive registration application.

Meanwhile, BioProspect has received a positive response from shareholders to its Share Purchase Plan (SPP), which will assist in the funding for the commercialisation of its range of natural products spanning the animal health, pest control, and human therapeutic and skin care markets.

“The Company’s SPP closes this weekend to shareholders on the register as of close of business Friday, May 7. Involving not only a discounted share issue free of brokerage and a loyalty options issue, this represents an attractive opportunity to invest in a fast-growing and sustainable Australian natural products provider, and I urge our loyal shareholders to consider this investment carefully,” Mr May said.

“BioProspect is also planning the launch of a new, investor-friendly website, and in anticipation of this we have updated our ASX/Media page with some of our recent media reports for the information of shareholders.

“We are focused on commercialising our natural product range encompassing not only *AGRIPRO*<sup>™</sup> products, but also the *REGEN*<sup>™</sup> range of natural therapeutic and skin care products and natural termite solution *TERMILONE*<sup>®</sup>. I am confident we can deliver successful outcomes for the benefit of shareholders.”

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Colin Johnston', written in a cursive style.

**COLIN JOHNSTON**  
Company Secretary

### *About EGUS*

One of the horse industry’s most common complaints, EGUS is a broad term used to describe a range of clinical and behavioural symptoms arising from the development of ulcers in a horse’s stomach.

Likely resulting from a combination of diet, stress-related activity and behaviour, EGUS causes poor performance and affects horses used in competitive activities such as dressage, racing and show jumping. According to some studies, up to 90 per cent of racehorses may suffer from EGUS, particularly those housed under cover on a continual basis.